HaystackAnalytics earns NABL-accredited for clinical genomics

New Delhi: After four years of transforming India’s diagnostics landscape through world-class science, deep-tech innovation, and clinically relevant solutions, HaystackAnalytics, a pioneer in genomics-based diagnostics, has earned accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL).

This milestone cements HaystackAnalytics’ position at the forefront of high-quality molecular diagnostic testing in India.

This NABL accreditation under ISO 15189:2022 validates the technical competence of HaystackAnalytics’ central sequencing facility in Navi Mumbai across a broad spectrum of next-generation sequencing (NGS)-based diagnostics in both infectious diseases and human genomics. Under infectious diagnostics it covers TB-ONE-NGS (drug resistance ), Flu-NGS (NGS based detection of respiratory pathogens), Infexn-NGS (NGS based detection of bacteria and fungi. Under human genomics we are accredited for tests under whole exome sequencing (WES) and pharmacogenomics (PGx).

The recognition reinforces HaystackAnalytics’ commitment to scientific and operational excellence, strengthens its credibility among clinicians, research institutions, and global health partners, and marks a key milestone in its mission to deliver high-quality, accessible, and scalable diagnostics solutions aligned with global standards.

Commenting on this milestone, “HaystackAnalytics has always prioritised regulatory excellence and quality. Earlier we received ISO13485 and CE-IVD certifications for our manufacturing facility. Further to our commitment to quality, we are now accredited by NABL for our clinical genomics products and services. We will continue to seek other certifications with the aspiration of establishing the highest global standards of quality at HaystackAnalytics.” said Dr. Anirvan Chatterjee, Co-founder & CEO of HaystackAnalytics. “In fields like genomics, where clinical impact hinges on accuracy and trust, this certification ensures that we are meeting the highest global standards, right here in India.”

“This accreditation is a pivotal step in our growth journey,” added Gaurav Srivastava, Co-founder & COO, HaystackAnalytics. “It not only boosts clinician and institutional confidence in our solutions but also strengthens our readiness for domestic and global partnerships. It aligns with our mission to make precision diagnostics accessible, applicable, and affordable for all.”

As a Quality Council of India initiative, NABL accreditation enables HaystackAnalytics to operate with enhanced trust, enabling deeper integration with hospitals, public health systems, and research institutions. With this accreditation, HaystackAnalytics continues to redefine diagnostics for India—making complex genomics simple, scalable, and impactful.